Allogeneic cell therapy company Mesoblast (ASX:MSB) has announced expanded US payer coverage for its Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the US FDA. …
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
GBMA welcomes Budget pathway to increasing biosimilar uptake
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Disappointment for diabetes advocates in response to Government budget silence
May 13, 2026 - - Latest News -
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 - - Latest News -
Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network
May 13, 2026 - - Latest News